126 related articles for article (PubMed ID: 38676528)
1. Substituted 4H-3,1-benzoxazine-4-one Derivatives as Inhibitors of Cathepsin G.
Aliter KF; Al-Horani RA
Med Chem; 2024 Apr; ():. PubMed ID: 38676528
[TBL] [Abstract][Full Text] [Related]
2. Sulphated penta-galloyl glucopyranoside (SPGG) is glycosaminoglycan mimetic allosteric inhibitor of cathepsin G.
Al-Horani RA; Afosah DK; Kar S; Aliter KF; Mottamal M
RPS Pharm Pharmacol Rep; 2023 Jan; 2(1):rqad001. PubMed ID: 36844783
[TBL] [Abstract][Full Text] [Related]
3. Homogeneous, Synthetic, Non-Saccharide Glycosaminoglycan Mimetics as Potent Inhibitors of Human Cathepsin G.
Afosah DK; Fayyad RM; Puliafico VR; Merrell S; Langmia EK; Diagne SR; Al-Horani RA; Desai UR
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238630
[TBL] [Abstract][Full Text] [Related]
4. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa.
Tans G; Janssen-Claessen T; Rosing J; Griffin JH
Eur J Biochem; 1987 May; 164(3):637-42. PubMed ID: 3552674
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil cathepsin G proteolysis of protease-activated receptor 4 generates a novel, functional tethered ligand.
Stoller ML; Basak I; Denorme F; Rowley JW; Alsobrooks J; Parsawar K; Nieman MT; Yost CC; Hamilton JR; Bray PF; Campbell RA
Blood Adv; 2022 Apr; 6(7):2303-2308. PubMed ID: 34883511
[TBL] [Abstract][Full Text] [Related]
6. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense.
Tausch L; Henkel A; Siemoneit U; Poeckel D; Kather N; Franke L; Hofmann B; Schneider G; Angioni C; Geisslinger G; Skarke C; Holtmeier W; Beckhaus T; Karas M; Jauch J; Werz O
J Immunol; 2009 Sep; 183(5):3433-42. PubMed ID: 19648270
[TBL] [Abstract][Full Text] [Related]
7. Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules.
Burster T; Macmillan H; Hou T; Schilling J; Truong P; Boehm BO; Zou F; Lau K; Strohman M; Schaffert S; Busch R; Mellins ED
Immunology; 2010 Jul; 130(3):436-46. PubMed ID: 20331476
[TBL] [Abstract][Full Text] [Related]
8. Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells.
Reich M; Lesner A; Legowska A; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Mol Immunol; 2009 Sep; 46(15):2994-9. PubMed ID: 19615749
[TBL] [Abstract][Full Text] [Related]
9. A new class of heterocyclic serine protease inhibitors. Inhibition of human leukocyte elastase, porcine pancreatic elastase, cathepsin G, and bovine chymotrypsin A alpha with substituted benzoxazinones, quinazolines, and anthranilates.
Teshima T; Griffin JC; Powers JC
J Biol Chem; 1982 May; 257(9):5085-91. PubMed ID: 7040392
[TBL] [Abstract][Full Text] [Related]
10. Coumarin and isocoumarin as serine protease inhibitors.
Pochet L; Frédérick R; Masereel B
Curr Pharm Des; 2004; 10(30):3781-96. PubMed ID: 15579071
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of cathepsin G: a patent review (2005 to present).
Kosikowska P; Lesner A
Expert Opin Ther Pat; 2013 Dec; 23(12):1611-24. PubMed ID: 24079661
[TBL] [Abstract][Full Text] [Related]
12. New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants.
Woodland MD; Thompson A; Lipford A; Goyal N; Schexnaildre JC; Mottamal M; Afosah DK; Al-Horani RA
ACS Omega; 2024 Mar; 9(9):10694-10708. PubMed ID: 38463342
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cathepsin G by 4H-3,1-benzoxazin-4-ones.
Gütschow M; Neumann U
Bioorg Med Chem; 1997 Oct; 5(10):1935-42. PubMed ID: 9370038
[TBL] [Abstract][Full Text] [Related]
14. Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G.
Ledoux D; Merciris D; Barritault D; Caruelle JP
FEBS Lett; 2003 Feb; 537(1-3):23-9. PubMed ID: 12606025
[TBL] [Abstract][Full Text] [Related]
15. Exogenous cathepsin G upregulates cell surface MHC class I molecules on immune and glioblastoma cells.
Giese M; Turiello N; Molenda N; Palesch D; Meid A; Schroeder R; Basilico P; Benarafa C; Halatsch ME; Zimecki M; Westhoff MA; Wirtz CR; Burster T
Oncotarget; 2016 Nov; 7(46):74602-74611. PubMed ID: 27806341
[TBL] [Abstract][Full Text] [Related]
16. Effective DNA inhibitors of cathepsin g by in vitro selection.
Gatto B; Vianini E; Lucatello L; Sissi C; Moltrasio D; Pescador R; Porta R; Palumbo M
Int J Mol Sci; 2008 Jun; 9(6):1008-1023. PubMed ID: 19325843
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin G deficiency reduces periaortic calcium chloride injury-induced abdominal aortic aneurysms in mice.
Wang J; Sukhova GK; Liu J; Ozaki K; Lesner A; Libby P; Kovanen PT; Shi GP
J Vasc Surg; 2015 Dec; 62(6):1615-24. PubMed ID: 25037606
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin G and its Dichotomous Role in Modulating Levels of MHC Class I Molecules.
Burster T; Knippschild U; Molnár F; Zhanapiya A
Arch Immunol Ther Exp (Warsz); 2020 Aug; 68(4):25. PubMed ID: 32815043
[TBL] [Abstract][Full Text] [Related]
19. Sulfonated Nonsaccharide Heparin Mimetics Are Potent and Noncompetitive Inhibitors of Human Neutrophil Elastase.
Al-Horani RA; Aliter KF; Kar S; Mottamal M
ACS Omega; 2021 May; 6(19):12699-12710. PubMed ID: 34056422
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
Cipolla D; Zhang J; Korkmaz B; Chalmers JD; Basso J; Lasala D; Fernandez C; Teper A; Mange KC; Perkins WR; Sullivan EJ
Respir Res; 2023 May; 24(1):133. PubMed ID: 37198686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
